From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management.

Interleukin(IL)-17 inhibitors display higher efficacy than both TNFi and IL-12/23i, which increased the goal psoriasis area severity index (PASI) from 75 to PASI 90 or even PASI 100. Ixekizumab, a recombinant, humanized IgG4 monoclonal antibody targeting IL-17A displayed a high efficacy and safety i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Dermatol Ther
Egile Nagusiak: Damiani, Giovanni, Conic, Rosalynn RZ, Pigatto, Paolo DM, Bragazzi, Nicola L, Pacifico, Alessia, Malagoli, Piergiorgio
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6579640/
https://ncbi.nlm.nih.gov/pubmed/30942952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.12886
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak